Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers. [electronic resource]
Producer: 20190729Description: e003939 p. digitalISSN:- 1941-7705
- Anticholesteremic Agents -- economics
- Biomarkers -- blood
- Cholesterol, LDL -- blood
- Databases, Factual
- Drug Costs
- Dyslipidemias -- blood
- Eligibility Determination -- economics
- Humans
- Medical Assistance -- economics
- PCSK9 Inhibitors
- Policy Making
- Prior Authorization -- economics
- Private Sector -- economics
- Proprotein Convertase 9 -- metabolism
- Serine Proteinase Inhibitors -- economics
- United States
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.